Form 4: IN8BIO Director Alan S. Roemer Acquires Shares and Amends Warrants

Director Alan S. Roemer reports acquisition of IN8BIO shares and amendment of existing warrants.

Summary

• On October 4, 2024, Alan S. Roemer, a director of IN8BIO, Inc., reported changes in beneficial ownership.
• Roemer acquired 126,582 shares of common stock as part of Issuer Units purchased at $0.395 per unit, with each unit including one share of common stock and one Series C warrant.
• Roemer also amended existing Series A warrants, resulting in the deemed cancellation of the old warrants and the grant of replacement warrants.
• The exercise price of the Series A warrants was reduced from $1.25 to $0.45, and the expiration date was extended from June 13, 2025, to October 4, 2025.
• Roemer also acquired Series A warrants with an exercise price of $0.45 and Series C warrants with an exercise price of $0.27.
• The Series A warrants are fully vested and exercisable.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and amendment of warrants could be seen as mildly positive, but it's not a major event.

Positives

• Director's acquisition of shares may signal confidence in the company's future prospects.
• The warrant amendment could make the warrants more attractive to exercise, potentially providing the company with additional capital.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the holdings of a director, which is a common occurrence.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.
• The warrant amendment could potentially lead to future dilution if the warrants are exercised.

Key Dates